Infectious disease
Ebola prevention trial in Congo enrolls more than 250 participants
The trial is testing an experimental antiviral pill given after suspected exposure to prevent Ebola from developing.

More than 250 people have enrolled in a trial in eastern Congo testing Gilead’s experimental antiviral pill obeldesivir after suspected exposure to Ebola, Medical Xpress reported. The trial began in July and is coordinated by ALIMA. Participants include health workers and relatives of patients who have been exposed to the disease but do not have symptoms.
The trial aims to recruit nearly 1,000 adults or children over the age of 12 who had contact with a confirmed case within the last five days. Half will receive a placebo. Participants are monitored daily for 21 days, with a final phone call after 42 days, according to a doctor working on the trial. The pill’s effectiveness has not been established. The Health Ministry figures reported by ABC News and STAT show 4,018 deaths among 8,300 cases since the outbreak was declared in eastern Congo on May 15. The trial targets Bundibugyo virus, Medical Xpress reported.
Reporting on this story
- ABC News An Ebola treatment center was burned down as the death toll in Congo passes 4,000 (opens in a new tab)
- STAT An Ebola treatment center was burned down as the death toll in Congo passes 4,000 (opens in a new tab)
- Medical Xpress Inside the study for a remedy to fight Congo's deadliest Ebola outbreak (opens in a new tab)


